首页> 外文期刊>Journal of Medicinal Chemistry >A combination of docking/dynamics simulations and pharmacophoric modeling to discover new dual c-Src/Abl kinase inhibitors
【24h】

A combination of docking/dynamics simulations and pharmacophoric modeling to discover new dual c-Src/Abl kinase inhibitors

机译:对接/动力学模拟和药效学建模相结合,发现新的双重c-Src / Abl激酶抑制剂

获取原文
获取原文并翻译 | 示例
           

摘要

A computational protocol was applied to identify molecular scaffolds untested toward the c-Src tyrosine kinase. A combination of docking and dynamics calculations allowed us to build three-dimensional models of the complexes between Src and several of its known inhibitors. Interactions most contributing to activity of the inhibitors, in terms of hydrogen bonds and hydrophobic contacts, were codified into pharmacophoric models that were in turn applied to perform a search of commercially available compounds within the Asinex database. As a result, we identified 1,3,4-thiadiazoles and pyrazolydine-3,5-diones showing inhibitory activity in the submicromolar range in a cell-free assay toward Src. Moreover, since several of the compounds used to generate pharmacophores were also known as Abl inhibitors, we tested the identified hits toward Ab1 tyrosine kinase, finding activity in the submicromolar range. Such biological data suggested that the computational protocol is an efficient tool for identifying new hits toward both Src and Abl.
机译:应用了一种计算方案来鉴定未经测试的针对c-Src酪氨酸激酶的分子支架。对接和动力学计算的结合使我们能够建立Src及其几种已知抑制剂之间复合物的三维模型。就氢键和疏水接触而言,对抑制剂活性最有帮助的相互作用已被编入药效学模型,该模型又被用于在Asinex数据库中进行市售化合物的搜索。结果,我们在无细胞测定中针对Src鉴定了在亚微摩尔范围内显示抑制活性的1,3,4-噻二唑和吡唑基-3,5-二酮。此外,由于几种用于产生药效基团的化合物也被称为Abl抑制剂,因此我们测试了对Ab1酪氨酸激酶的鉴定,发现其活性在亚微摩尔范围内。此类生物学数据表明,计算协议是用于识别针对Src和Abl的新命中的有效工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号